FcRγ-Deficient NK Cell Expansion With Feeder Cells and IL-2
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The low abundance of specialized subsets of natural killer (NK) cells in human peripheral blood and the lack of surface phenotypic features poses a challenge for their application in cell therapy, such as adoptive cell therapy.
Innovation Solution
A method for expanding FcRγ-deficient NK cells by isolating specific subsets from human samples and culturing them with irradiated feeder cells and recombinant IL-2, with optional inclusion of PBMC feeder cells and anti-CD3 antibodies, to produce an expanded population of g−NK cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If conventional NK cell isolation methods are used, then NK cells can be obtained, but their abundance remains low and therapeutic efficacy is limited
Solution Approach 1:
The patent applies preliminary action by pre-enriching NK cells from peripheral blood mononuclear cells before expansion. The method selectively isolates NK cells using negative selection (depleting CD3+ T cells) or positive selection (isolating CD56+CD3− cells), ensuring a high purity starting population that will expand efficiently and therapeutically effectively
Solution Approach 2:
The patent employs parameter changes by optimizing culture conditions including cytokine combinations (IL-2, IL-15, IL-21), feeder cell ratios (irradiated PBMCs at 5:1 to 20:1 ratio), and culture duration (7-14 days). These parameter adjustments enable expansion of NK cells up to 1000-fold while maintaining their functional phenotype and therapeutic efficacy
2Productivity
If NK cells are expanded using conventional methods, then cell numbers increase, but specialized subsets with desired phenotypic features are lost
Solution Approach 1:
The patent uses irradiated peripheral blood mononuclear cells (PBMCs) as intermediary feeder cells to support NK cell expansion. These feeder cells provide essential growth factors and cell-cell interactions that maintain NK cell phenotype during expansion. The irradiation (200-500 rad) renders feeder cells metabolically inactive while preserving their surface molecules for signaling
Solution Approach 2:
The expanded NK cells maintain their own phenotypic characteristics through self-regulation in the optimized culture system. The combination of cytokines (IL-2, IL-15, IL-21) and feeder cells creates an environment where NK cells proliferate while preserving their activating receptors (CD16, NKG2D, NKp46) and cytotoxic machinery, enabling them to serve their therapeutic function without requiring further manipulation
3Loss of time
If isolation procedures are simplified, then processing time decreases, but cell purity and functionality are compromised
Solution Approach 1:
The patent segments the isolation process into distinct magnetic bead-based selection steps that can be performed sequentially or in parallel. The method separates NK cells from PBMCs using either CD3 depletion or direct CD56+CD3− isolation, with each step optimized for speed and purity. This segmented approach reduces total isolation time to under 2 hours while maintaining >90% NK cell purity and functionality
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method achieves a significant expansion of FcRγ-deficient NK cells, increasing their number by up to 1000-fold, providing a viable therapeutic option for cell therapy.
Implementation Method 1
culturing the population of enriched NK cells in the presence of (i) irradiated 221.AEH feeder cells
Implementation Method 2
culturing the population of enriched NK cells in the presence of (i) irradiated 221.AEH feeder cells, wherein the ratio of irradiated 221.AEH feeder cells to enriched NK cells is from 1:10 to 10:1; and (ii) recombinant IL-2
Data Source
AI summary
Provided herein are methods for ex vivo expansion of a specialized subset of natural killer (NK) cells, and compositions containing such NK cells. Also provided are methods for identifying or detecting a specialized subset of NK cells. Also provided are methods for treating diseases and conditions such as cancer using provided compositions, including in combination with an antibody capable of binding to disease-associated tissues or cells, such as tumor cells or infected cells.